91,645 Shares in Bristol Myers Squibb Company $BMY Acquired by 1832 Asset Management L.P.

1832 Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 91,645 shares of the biopharmaceutical company’s stock, valued at approximately $4,242,000.

Several other large investors have also recently made changes to their positions in BMY. CW Advisors LLC grew its position in Bristol Myers Squibb by 33.5% during the 2nd quarter. CW Advisors LLC now owns 334,309 shares of the biopharmaceutical company’s stock worth $15,475,000 after acquiring an additional 83,835 shares during the last quarter. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $40,000. Groupe la Francaise grew its holdings in shares of Bristol Myers Squibb by 2,213.5% in the second quarter. Groupe la Francaise now owns 2,059 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 1,970 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Bristol Myers Squibb by 428.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after buying an additional 9,171,098 shares during the period. Finally, D L Carlson Investment Group Inc. raised its holdings in Bristol Myers Squibb by 78.2% during the 2nd quarter. D L Carlson Investment Group Inc. now owns 44,126 shares of the biopharmaceutical company’s stock valued at $2,043,000 after buying an additional 19,363 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Up 0.4%

Shares of NYSE:BMY opened at $52.16 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The stock has a fifty day simple moving average of $46.21 and a two-hundred day simple moving average of $46.78. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The stock has a market capitalization of $106.18 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 7.95 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company’s revenue was up 2.8% on a year-over-year basis. During the same period last year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd were issued a $0.62 dividend. The ex-dividend date of this dividend was Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 83.78%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a research note on Wednesday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Scotiabank reiterated a “sector perform” rating and issued a $53.00 price target (up previously from $45.00) on shares of Bristol Myers Squibb in a report on Thursday. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $55.25.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.